2020年3月31日 星期二

先前技術之間的「累積效應」影響是否啟始IPR審理 - Oticon v. Cochlear (IPR2019-00975, PTAB 2019)

本篇討論USPTO提出作為先例(precedential)的IPR案:Oticon Medical AB v. Cochlear Limited (IPR2019-00975) (PTAB Oct. 16, 2019),案件涉及是否與過去審查歷史有相同理由的爭議(35 U.S.C. § 325(d)),與前兩次討論(IPR2019-01469IPR2019-01042)拒絕啟始的決定相反。(另有關於「reasonable likelihood of prevailing(合理的勝訴可能性)」的不錯的提醒

經查,其中很重要的議題是,先前技術之間的累積效應(cumulative)。

IPR2019-00975案件資訊:
IPR異議人:OTICON MEDICAL AB; OTICON MEDICAL LLC; WILLIAM DEMANT HOLDING A/S
專利權人:COCHLEAR LIMITED
系爭專利:US9,838,807 (IPR2019-00975)

本案緣起Oticon對Cochlear的專利'807提起IPR異議,PTAB根據雙方提出資料決定啟始系爭專利的IPR審查。啟始理由主要是:審查官根據雙方提出的異議理由、初步回應等資料初判異議人提出異議理由具有可以撤銷其中至少一項專利範圍專利權的合理的勝訴可能性("reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition")。涉及法條:35 U.S.C. 31135 U.S.C. 313、35 U.S.C. 314(a)

系爭專利US9,838,807關於醫用的義肢(耳部)骨錨固定器,系爭專利的技術在於結構特徵,還可傳遞聲音。


1. An anchoring fixture for anchoring a prosthesis to a skull bone comprising:
a screw thread apparatus including a screw thread having a varying outer diameter;
a flange configured to function as a stop for the anchoring fixture adapted to rest on top of the bone when the anchoring fixture is implanted into the bone; and
a circumferential groove located, with respect to a side of the flange, on the anchoring fixture on a threaded side of the anchoring fixture,
wherein the anchoring fixture is configured for anchoring a hearing prosthesis component to the skull bone at a location behind an external ear so that sound is transmitted from the hearing prosthesis via the skull bone to the cochlea.

主要討論議題:35 U.S.C. § 325(d)

IPR異議理由:

WO 98/55049 (“Håkansson”)
US 6,981,873 B2 (“Choi”)
WO 2006/065205 A1 (“Brånemark”)
US 7,074,222 B2 (“Westerkull ’222”)
US 7,116,794 B2 (“Westerkull ’794”)

面對異議理由,先解釋專利範圍,依照案例"Phillips v. AWH Corp (Fed. Cir. 2005)",發明相關領域一般技術人員參照說明書與其審查歷史以通常與慣用的意思來解釋專利範圍("...the words of a claim are generally given their “ordinary and customary meaning,” which is the meaning they would have to a person of ordinary skill in the art at the time of the invention, in light of the specification and prosecution history.")。

(技術細節就不在此討論)


案件涉及「35 U.S.C. § 325(d)」有關PTAB可以拒絕啟始/審理過去已經審理過的理由,包括相同或實質相同的先前技術以及論點,除非異議人可以證明當時審理有誤。


針對325(d)議題,考量的是「Becton Dickinson factors」:
(a) the similarities and material differences between the asserted art and the prior art involved during examination;
(b) the cumulative nature of the asserted art and the prior art evaluated during examination;
(c) the extent to which the asserted art was evaluated during examination, including whether the prior art was the basis for rejection;
(d) the extent of the overlap between the arguments made during examination and the manner in which Petitioner relies on the prior art or Patent Owner distinguishes the prior art;
(e) whether Petitioner has pointed out sufficiently how the Examiner erred in its evaluation of the asserted prior art; and
(f) the extent to which additional evidence and facts presented in the Petition warrant reconsideration of the prior art or arguments.

以下為PTAB針對"Becton Dickinson Factors"結論(回應專利權人的答辯):

- Becton Dickinson factors (a),(b): 本次異議理由採用的前案Choi過去並未被審理過。編按,這裡有個句子"cumulative nature of the asserted art",就是指即便引用前案不是同一案,但前後採用的前案有「累積效應(cumulative effect)」,但被PTAB否決。

過去審理用的前案Härle


本次異議理由使用的Choi:


USPTO審查委員曾於過去審查中引用Härle作為新穎性核駁引證案,與本次引用Choi中的"circumferential groove"結構不同,不會形成"累積效應(cumulative)"。(重要)

(重要)PTAB意見:"We observe that Choi is a different reference than Härle beyond the fact that Choi’s grooves are structurally different than Härle’s grooves and serve a different purpose."

- Becton Dickinson factors (c),(d): 查核系爭專利的審查歷史,PTAB委員認為,即便本次異議理由的前案「Westerkull ’794, Westerkull ’222, and Håkansson」曾被USPTO審查專利時考量過,但另一案Choi並未被考量,仍不足以讓PTAB拒絕審理

(編按,因此上述有關「累積效應」的判斷影響本案最終是否啟始的判斷)

"There is new, noncumulative prior art asserted in the Petition, e.g., Choi. For at least this reason, we determine not to exercise our discretion under § 325(d) to deny the Petition on this basis."

Becton Dickinson factors (e),(f): 因為以上判定,就不論此要素。

最後是103判斷,證明異議人已經證明系爭專利中至少一項範圍有被撤銷的合理的勝訴可能性!

結論:

We conclude that Petitioner has demonstrated a reasonable likelihood of prevailing on its assertion that claims 1–12, 14, 16, 17, 25, 28, 33–35, 37–41, and 45–47 of the ’807 patent are unpatentable.


相關法條:
35 U.S.C. 311 INTER PARTES REVIEW.
(a) IN GENERAL.—Subject to the provisions of this chapter, a person who is not the owner of a patent may file with the Office a petition to institute an inter partes review of the patent. The Director shall establish, by regulation, fees to be paid by the person requesting the review, in such amounts as the Director determines to be reasonable, considering the aggregate costs of the review.
(b) SCOPE.—A petitioner in an inter partes review may request to cancel as unpatentable 1 or more claims of a patent only on a ground that could be raised under section 102 or 103 and only on the basis of prior art consisting of patents or printed publications.
(c) FILING DEADLINE.*—A petition for inter partes review shall be filed after the later of either—
(1) the date that is 9 months after the grant of a patent; or

(2) if a post-grant review is instituted under chapter 32, the date of the termination of such post-grant review.

35 U.S.C. 313 PRELIMINARY RESPONSE TO PETITION.

If an inter partes review petition is filed under section 311, the patent owner shall have the right to file a preliminary response to the petition, within a time period set by the Director, that sets forth reasons why no inter partes review should be instituted based upon the failure of the petition to meet any requirement of this chapter.

35 U.S.C. 314 INSTITUTION OF INTER PARTES REVIEW.

(a) THRESHOLD.—The Director may not authorize an inter partes review to be instituted unless the Director determines that the information presented in the petition filed under section 311 and any response filed under section 313 shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.
...

IPR決定:IPR2019-00975(備份:https://app.box.com/s/u5xoh72fitvhgqz4o42ij68o1r8ow0iw

Ron

2020年3月27日 星期五

PTAB拒絕重複審理過去已提過的理由 - PUMA v. NIKE (IPR2019-01042)

本案例「PUMA North America, Inc. v. NIKE, Inc. (IPR2019-01042)」如同日前報導的「PTAB有權拒絕相同理由的異議案 - Advanced Bionics v. Med-El elektromedizinische (PTAB)」,都是討論35 U.S.C. § 325(d)規定不必重複審理「相同異議/核駁理由」的案例。

PUMA v. NIKE (IPR2019-01042)案件資訊:
專利權人:NIKE, INC.
IPR異議人:PUMANORTH AMERICA, INC.
系爭專利:US9,314,065 (IPR2019-01042)

本案緣起PUMA對Nike的'065專利提起IPR異議,異議理由如下:

Anderton: U.S. Patent No. 5,461,801

Auger: U.S. Patent No. 8,056,267


'065專利關於鞋底的釘狀結構,結果用發明專利來寫,還有點複雜!






1. An article of footwear comprising:
a base plate including a forefoot region, a heel region, a midfoot portion disposed between the forefoot region and the heel region, a longitudinal axis extending through the forefoot region and heel region, a forward edge, a rearward edge, a medial edge, and a lateral edge;
a structure disposed on the base plate, the structure including a medial forefoot pad disposed on the forefoot region proximate the midfoot portion and the medial edge, a lateral forefoot pad disposed on the forefoot region proximate the midfoot portion and the lateral edge, a medial heel pad disposed on the heel region proximate the medial edge, a first lateral heel pad disposed on the heel region proximate the lateral edge, a first diagonal rib extending from the medial forefoot pad to the first lateral heel pad, a second diagonal rib extending from the lateral forefoot pad to the medial heel pad, a medial midfoot bar substantially parallel to the longitudinal axis and disposed proximate the medial edge, and a lateral midfoot bar substantially parallel to the longitudinal axis and disposed proximate the lateral edge;
a medial forefoot stud disposed on the medial forefoot pad;
a medial heel stud disposed on the medial heel pad;
a first lateral forefoot stud disposed on the lateral forefoot pad; and
a first lateral heel stud disposed on the first lateral heel pad;
the first diagonal rib having a first lateral edge intersecting with the first lateral heel pad;
the second diagonal rib having a second lateral edge intersecting with the first lateral forefoot pad;
the lateral midfoot bar having a third lateral edge;
wherein the medial midfoot bar extends from a first point on the first diagonal rib to a second point on the second diagonal rib; and
wherein the third lateral edge of the lateral midfoot bar intersects with, and terminates at, a third point on the second diagonal rib at a forward end of the lateral midfoot bar;
wherein the third lateral edge of the lateral midfoot bar intersects with, and terminates at, a fourth point on the first diagonal rib at a rearward end of the lateral midfoot bar;
wherein the third point is spaced from the lateral forefoot pad; and
wherein the fourth point is spaced from the first lateral heel pad.

用文字界定出鞋底結構還真的有些複雜,連命名都是:
first medial heel stud 132
second medial forefoot stud 134
first lateral forefoot stud 136
second lateral forefoot stud 138
third lateral forefoot stud 140
first center stud 142

second center stud 144
...

解釋專利範圍:

此案異議審理時,PTAB審查官提出解釋專利範圍的圓則是,應與此案在之前民事(侵權訴訟)案中的解釋標準一致,並採用Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005)案所帶出的解釋原則。

判斷系爭專利是否具備非顯而易知性(35 U.S.C. 103),引用案例KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 406 (2007)Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966),原則上就是分析出系爭案專利範圍與先前技術的差異後,判斷兩者差異是否具備非顯而易知性的客觀證據,也就是由相關領域一般技術人員判斷發明當時是否已經是顯而易見了,以及是否先前技術的組合已經產生可預期如系爭案發明的結果。

摘錄這裡採用「Level of Ordinary Skill in the Art」的定義(異議人主張,大家都無異議):相關領域實際工作2~4年的經驗者,還有學歷要求。
"a person of ordinary skill in the art at the relevant time would have had “at least an undergraduate degree in consumer or industrial product design, engineering, or a related field, or at least around 2–4 years of practical work experience in the design and development of athletic footwear.”"

35 U.S.C. § 325(d)議題:

解釋專利範圍的預備工作後,議題轉向:35 U.S.C. § 325(d),由於主管機關(PTAB)認為相同或實質相同的先前技術與論述都已經在之前審查過程中提出,因此否決啟始本案。

與前篇討論一樣,採用「Becton Dickinson factors」,參考過去報導:AIA審判實務指南(TPG)筆記(https://enpan.blogspot.com/2018/08/aia-trial-practice-guide-tpg.html

Becton Dickinson factors
(a) the similarities and material differences between the asserted art and the prior art involved during examination;
(b) the cumulative nature of the asserted art and the prior art evaluated during examination;
(c) the extent to which the asserted art was evaluated during examination, including whether the prior art was the basis for rejection;
(d) the extent of the overlap between the arguments made during examination and the manner in which Petitioner relies on the prior art or Patent Owner distinguishes the prior art;
(e) whether Petitioner has pointed out sufficiently how the Examiner erred in its evaluation of the asserted prior art; and
(f) the extent to which additional evidence and facts presented in the Petition warrant reconsideration of the prior art or arguments.

Becton Dickinson factors (a): 大家都同意本次提出引證案與過去審理過的前案一樣,都是Anderton and Auger
Becton Dickinson factors (b): 因為(a)的結論,不用檢查(b)了。 
Becton Dickinson factors (c): 大家都同意本次提出異議理由與過去103議題審委採用的理由一樣。
Becton Dickinson factors (d): 經查本次異議理由與過去的審查意見(查的很詳細)論點,重疊性很高。
Becton Dickinson factors (e): 異議人並未成功地證明過去審查意見有錯(這部分等於異議人要重複提出103相關技術討論,如果與過去一致,也就沒有證明之前有錯!)。
Becton Dickinson factors (f): 此要件是要考量異議理由中是否有額外證據,以及提出的證據是否足夠推翻過去結論,結果PTAB認為異議人提出專家證詞並不足以證明與過去不同而能反駁過去審理意見。

最終,PTAB拒絕啟始本案,理由是異議人的主張已經在過去程序中提過,並且也未能證明審查意見有錯。

本篇IPR決定主要篇幅即圍繞在這六個要件上,可以成為日後採用"Becton Dickinson factors"而拒絕啟始與審理案件的參考。

PTAB決定:
PUMA North America, Inc. v. NIKE, Inc., IPR2019-01042 (PTAB Oct. 31, 2019)(備份:https://app.box.com/s/5yvyiakmo1ktf6tufbucpc5z03b5q49c

Ron

2020年3月26日 星期四

COVID-19相關藥品的資訊

新冠病毒疫情指揮中心於3/26/2020提出可能治療病人的用藥資訊:


這裡提到建議學名藥是一種治療瘧疾的藥:hydroxychloroquine(羥氯喹)

查到的資料:


之前在「「remdesivir」的台灣專利(https://enpan.blogspot.com/2020/03/remdesivir.html」討論過TIPO列出「國際上臨床試驗藥物的我國相關專利資訊」,其中列出I687432案,這裡也合併網路上討論Gilead公司所提出可能成為「COVID-19」用藥的專利申請案。

補充:GPSS檢索條件:((Gilead and US)@PA AND (62/072,331)@PB),經去重後可得出30件多國專利(申請、公告)。

--------------------------------------
列舉US9724360,此案對應台案:I687432


Claim 1(根據審查歷史,即便歷經101, 102核駁意見,範圍最後還異常地放寬...)


--------------------------------------
專利公告號:I687432
專利名稱:絲狀病毒科病毒感染之治療(METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS)
公告號:2020/03/11
申請日:2015/10/27
申請號:104135247
優先權:
美國 62/072,331 20141029
美國 62/105,619 20150120

申請人:美商基利科學股份有限公司 GILEAD SCIENCES, INC.

Claim 1(公告核准,此專利範圍千萬不能只看網頁公告的文字版,因為看不到化學符號):


--------------------------------------
另有一件相關申請案,不過這件已經結案了!

專利公開號:TW 201733595
名稱:用於治療沙狀病毒及冠狀病毒感染之方法(METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS)
申請日:2016/09/19
申請號:105130244
優先權:
美國 62/219,302 20150916
美國 62/239,696 20151009
申請人:基利科學股份有限公司 GILEAD SCIENCES, INC.

Claim 1:(橫跨6頁A4紙)




本案最新狀態是:結案(未申請實審)


其他參考:
如果將過去獲准專利改寫為「治療2019年新冠病毒的藥品」用途專利,並非不可,但仍要符合用途專利的獲准要件:

參考我國專利審查基準第二篇第3章2.5.2「以用途界定物之請求項」與2.5.3「用途請求項」兩節的說明:

以用途界定物之請求項,應解釋為所請求保護之物適合用於所界定之特殊用途,至於實際的限定作用,則取決於該用途特徵是否對所請求保護之物產生影響,亦即該用途是否隱含申請專利之物具有適用該用途之某種特定結構及/或組成

用途請求項之可專利性在於發現物之未知特性後,根據使用目的將該物使用於前所未知之特定用途,故通常係僅適用於經由物的構造或名稱較難以理解該物應如何被使用的技術領域,例如化學物質之用途的技術領域。關於機器、設備及裝置等物品發明,通常該物品具有固定用途,故其以用途作為申請標的通常不具新穎性。


2019新型冠狀病毒的藥品專利?用途專利討論(https://enpan.blogspot.com/2020/02/2019.html

Ron

著作權免責使用的平衡問題 - Allen v. Cooper (Supreme Court 2020)

本篇討論美國最高法院對於「著作權(copyright)」免責範圍的判決。

案件資訊:
原告/著作權人:ALLEN ET AL.
被告:COOPER, GOVERNOR OF NORTH CAROLINA, ET AL.(北卡州長)

本案緣起著作權人Allen對被加州(州長)使用其著作(教育用途)提出著作權侵權告訴,著作有關Allen拍攝有關探勘Pirate Blackbeard沈船的影像。

爭議關於美國憲法11th修正案內容:

"The Judicial power of the United States shall not be construed to extend to any suit in law or equity, commenced or prosecuted against one of the United States by Citizens of another State, or by Citizens or Subjects of any Foreign State."

是否免責,有很多角度的意見在拉扯,法官之間也是,政府一方面要保護著作權人的智慧財產獨佔權,可以排除他人使用,另一方面又不容國會讓州政府在聯邦法院提起私人訴訟,但在14th修正案中不准政府剝奪個人權利,美國憲法Article I並沒有准許國會可以限制州政府的免責權。

根據本案最高法院意旨,在Syllabus的第一句話先交代本次系爭著作權的起源,1996年,有一間打撈公司Intersal在北卡羅來納州沿海發現了「安妮女王的複仇號(Queen Anne’s Revenge)」的沉船。(可參考:https://en.wikipedia.org/wiki/Queen_Anne%27s_Revengehttp://www.lat3440.com/queen-annes-revenge/

本案緣起,北卡州政府成為這艘沈船的擁有者,與打撈業者Intersal簽約打撈沈船,Intersal僱用本案原告攝影作者Frederick Allen協助拍攝影片,取得超過10年的影像,並註冊了著作權。

被卡政府將Allen拍攝的部分影像放在網路上,Allen就對州政府提出侵權告訴,但州政府撤銷訴訟,理由是州政府具備免責權,這時,Allen主張在「(Copyright Remedy Clarification Act of 1990 (CRCA))」已經移除州政府使用著作權的免責權,當時地方法院同意CRCA已經移除州政府的免責權。

用Google影像搜尋"frederick allen shipwreck",可以得到很多相關沈船的畫面,十分精彩:


但是案件進入最高法院時,卻認為國會無權剝奪州政府的對於著作權使用的免責權。

strong evidence v. thin evidence

雖Allen主張,著作權,亦如專利權,政府允許發明人/著作權人對其發明/著作有獨佔權,也能排除州政府的使用,但"Florida Prepaid"否決這個看法。最高法院認為,專利侵權是一個蓄意行為,且沒有適當的國家級補償措施,而類似地,CRCA用於回應這類強而有力的違反憲法的侵權行為的證據,不過,對於本案例而言,屬於薄弱證據的侵權行為,如"Florida Prepaid",不如CRCA,相關記錄並不支持可以剝奪州政府的免責權。

"Congress lacked authority to abrogate the States’ immunity from copyright infringement suits in the CRCA."

"...the scope of unconstitutional patent infringement as intentional conduct for which there is no adequate state remedy."

"But as in Florida Prepaid, the legislative record contains thin evidence of infringement. Because this record cannot support Congress’s choice to strip the States of their sovereignimmunity in all copyright infringement cases, the CRCA fails the “congruence and proportionality”"

這個判決與"平衡"法律保障的救濟與預防傷害,甚至是使用的態樣有關。

"For Congress’s action to fall within its Section 5 authority, “there must be a congruence and proportionality between the injury to be prevented or remedied and the means adopted to that end.”"

參考畫面:
https://www.courthousenews.com/fourth-circuit-rules-north-carolina-immune-from-filmmakers-lawsuit/


my two cents:
本篇僅是我的小小理解,實際是很難懂的,雖法官都同意這個判決,但都有對法條理解的誤差,顯然除了英文問題外,還有法律素養的問題!

最高法院判決:
https://www.supremecourt.gov/opinions/19pdf/18-877_dc8f.pdf(備份:https://app.box.com/s/nkmlm5uw7de0bxkmpo7e9q7moaungjyz

資料參考:
https://patentlyo.com/patent/2020/03/infringing-copyright-immunity.html
https://www.courthousenews.com/fourth-circuit-rules-north-carolina-immune-from-filmmakers-lawsuit/

Ron

2020年3月25日 星期三

PTAB有權拒絕相同理由的異議案 - Advanced Bionics v. Med-El elektromedizinische (PTAB)

以下幾件案例為USPTO/PTAB指定為先例(precedential)或有資訊價值的案件:

- Advanced Bionics, LLC v. MED-EL Elektromedizinische Geräte GmbH, IPR2019-01469 (PTAB Feb. 13, 2020) (Paper 6) (precedential)
- PUMA North America, Inc. v. NIKE, Inc., IPR2019-01042 (PTAB Oct. 31, 2019) (Paper 10) (informative)
- Oticon Medical AB v. Cochlear Limited, IPR2019-00975 (PTAB Oct. 16, 2019) (Paper 15) (precedential as to sections II.B and II.C)

USPTO資訊:PTAB designates two decisions as precedential and one decision as informative

--------------------------

本篇討論案例為「Advanced Bionics, LLC v. MED-EL Elektromedizinische Geräte GmbH, IPR2019-01469 (PTAB Feb. 13, 2020) (Paper 6) (precedential)」

此為PTAB拒絕啟始(institution)的案例,涉及35 U.S.C. § 325(d)規定:若提出異議程序的之前已經有另一審理案件(針對相同專利),且已經作出決定或是在審理中,USPTO主管可以決定如何續行:擱置、轉手、合併或終止。特別指相同系爭專利在另一程序中也遇到相同或實質相同的先前技術而言。

35 U.S.C. § 325(d)
35 U.S.C. 325 RELATION TO OTHER PROCEEDINGS OR ACTIONS

...
(d) MULTIPLE PROCEEDINGS.—Notwithstanding sections 135(a), 251, and 252, and chapter 30, during the pendency of any post- grant review under this chapter, if another proceeding or matter involving the patent is before the Office, the Director may determine the manner in which the post-grant review or other proceeding or matter may proceed, including providing for the stay, transfer, consolidation, or termination of any such matter or proceeding. In determining whether to institute or order a proceeding under this chapter, chapter 30, or chapter 31, the Director may take into account whether, and reject the petition or request because, the same or substantially the same prior art or arguments previously were presented to the Office.

本文標題是「PTAB有權拒絕相同理由的異議案 - Advanced Bionics v. Med-El elektromedizinische (PTAB)」,主要討論是何謂「相同理由(證據、論點)」?

案件資訊:
IPR異議人:ADVANCED BIONICS, LLC
專利權人:MED-EL ELEKTROMEDIZINISCHE GERÄTE GMBH
系爭專利:US8,634,909 (claims 1, 3, 5, 6, 10, 11, 14, 16, and 20,IPR2019-01469)

US8,634,909關於一種可植入病患體內的磁性裝置,指的是電子耳。
一般電子耳中有磁鐵,當病患接受磁振造影檢查時,此電子耳會被影響,使得其中磁鐵位移,甚至造成耳內組織損害,但系爭專利提出的裝置內有可旋轉磁鐵,磁極平行其中線圈平面殼體,其磁化方向平行人體皮膚,可避免被磁化(進入MRI)時形成轉矩,也就不會產生位移。


Claim 1:
1. An implantable system for a recipient patient, the implantable system comprising:
a coil housing configured to be implanted under the patient's skin, the coil housing having a planar outer surface configured to lie parallel to the patient's skin and containing a signal coil for transcutaneous communication of an implant communication signal; and
a planar disc shaped first attachment magnet within the coil housing, the first attachment magnet adapted to be rotatable therein, having a magnetic dipole moment oriented across a diameter of the first attachment magnet, and configured within the coil housing such that the magnetic dipole moment remains substantially parallel to the planar outer surface of the coil housing when the first attachment magnet rotates for transcutaneous magnetic interaction with a corresponding second attachment magnet.

IPR的103異議理由:

U.S. Pat. No. 6,838,963 B2, issued Jan. 4, 2005 (“Zimmerling”)
U.S. Pat. No. 7,266,208 B2, issued Sept. 4, 2007 (“Charvin”)
U.S. Pat. App. Pub. No. US 2009/0005836, published Jan. 1, 2009 (“Chang”)
U.S. Pat. No. 6,761,681 B2, issued July 13, 2004 (“Schmid”)

這時,根據專利權人意見,議題轉向35 U.S.C. § 325(d),是否在此異議案之前已經提交過(previously presented)相同或實質相同的前案或論點(art or arguments)

何謂「之前已經提交過的先前技術與論點」?

"Under § 325(d), the art and arguments must have been previously presented to the Office during proceedings pertaining to the challenged patent."

文中表示包括:"審查委員記錄中的前案"、"申請人提供給專利局的先前技術(如IDS)"、"系爭專利的審查歷史"。

與提交的先前技術有關的的程序如:專利審查程序、再審程序(reexamination)、再領證程序,以及AIA的異議程序。

如何應用35 U.S.C. § 325(d),這裡提出two-part framework:

(1) whether the same or substantially the same art previously was presented to the Office or whether the same or substantially the same arguments previously were presented to the Office; and (2) if either condition of first part of the framework is satisfied, whether the petitioner has demonstrated that the Office erred in a manner material to the patentability of challenged claims.

第一:是否先前已經提交相同或實質相同的先前技術與論點給審理機關(PTAB)?
第二:符合上述條件,是否異議人證明審理機關的審理有誤?

如果符合"第一點"情況,即表示主管機關可以拒絕審理本次異議案,除非,異議人可以證明之前審理評估所述先前技術與論點有錯。若異議人無法證明先前審理有錯,本次審查官可以否決啟始IPR

其中,「相同」的前案或論點不難判斷,但是,如何判斷「相同或實質相同」的前案或論點?

這裡又引用了「Becton, Dickinson factors」。這個判斷要素提出,所述「先前提交的前案或論點」是要在「此AIA程序前的任何審理期間(during examination)」提出的。如此可知,如果並未被審查委員引用的前案,可能不算是已經提交過的證據(先前技術)。而且,若要證明「之前審查有誤」,要證明先前審查時對先前技術的考慮是錯的,或是甚至沒有正確引用。

關於本案,PTAB審理此議題時,很仔細地查閱過去審理機關的審理與答辯過程。經查,其實本次IPR提出證據與過去審理期間的引用前案"不同",但是吊詭的是,先前引用前案與本次證據有實質相同的"資訊",如Charvin與Zimmerling,以下節錄圖示,當然還是要看看其中內容細節,以及核駁引用段落而定(編按,都是有關平面磁性物體、線圈、可旋轉磁鐵等)。

同樣地,對於前案Chang、Schmid與Zimmerling也是類似的判斷。

Charvin


Zimmerling


Chang


Schmid


根據其中前案給的資訊(編按,這種解釋超廣),加上異議人並未證明先前審理意見有誤,PTAB的審查官認為,本案異議理由已經符合35 U.S.C. § 325(d)可以拒絕啟始的條件了!





my two cents:
雖本篇有點傻眼,但給我的信息是,趁著專利審理過程,充分利用IDS、情報提供,可能可以減少將來的爭議,不過,類訴訟的IPR又是很嚴格地看證據,即便有此precedential,仍是充滿了不確定的因素。

IPR決定:https://www.uspto.gov/sites/default/files/documents/IPR2019-01469%20DDI%2C%20Advanced%20Bionics%20p.pdf?utm_campaign=subscriptioncenter&utm_content=&utm_medium=email&utm_name=&utm_source=govdelivery&utm_term=(備份:https://app.box.com/s/6pittf4jzsrvht1ejzsa3y30sawbqvti

Ron